BIOCORP
27.9.2021 06:47:07 CEST | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, today announces an agreement with Novo Nordisk, a world leader in diabetes care, for the development and distribution (pending successful development) of a Mallya smart add-on device for the Novo Nordisk FlexTouch pen used by people with diabetes.
Mallya is a Bluetooth enabled smart add-on device for pen injectors that collects dose and time of each injection and transfers information in real time to a companion software. Mallya helps people with diabetes maintain a reliable dose log, using technology to help improve understanding and allowing people to dose with confidence.
Most Novo Nordisk's insulins are offered with the FlexTouch pen, and it is part of the launch map for all new insulins. A specific version of Mallya will be developed for FlexTouch, the first prefilled insulin delivery device with no-push-button extension. Due to the unique dosing mechanism of FlexTouch, the push button does not extend at any dose and allows insulin to be administered by pressing the low injection force button. The existing Mallya device had to be redesigned to meet the needs of this mechanism, keeping its accuracy and reliability for the patient.
Directly attached on the disposable pre-filled FlexTouch pen, Mallya will allow seamless and efficient dose logging on FlexTouch, which could help people with diabetes and their HCPs to have more personalized conversations about the disease and treatment compliance.
Biocorp will receive an upfront payment and different milestones are defined staging the development phase. Upon successful development, Novo Nordisk plans to distribute the smart device in selected countries, and Biocorp expects to ramp up production volumes from 2022. Financials and terms of contract are not disclosed.
“Novo Nordisk collaborates with Biocorp as we believe people with diabetes deserve the freedom to decide which solution works best for them. Our Swedish study1 demonstrates the health benefits associated with the use of smart insulin pens. And as we continue launching such smart pens, we also partner with Biocorp to allow even more people with diabetes to reap the benefits connected devices can provide. This collaboration demonstrates our commitment to making diabetes management easier by giving people access to data on medication usage behaviour which is known to potentially result in improved patient outcomes”, said Søren Smed Østergaard, vice president of Digital Health at Novo Nordisk.
“Biocorp is very proud to sign this partnership with the world's leading diabetes company, Novo Nordisk, and it is a huge recognition for our Mallya. Providing almost 50% of the insulin used worldwide, Novo Nordisk distributed more than 500 million insulin pens in 2020, treating close to 30 million patients. The FlexTouch pen is not concerned by Mallya's current version, while used by tens of millions of patients with diabetes in the world, so we are pleased to be working to open up the possibilities of connectivity for the many patients around the world who use this pen. ”, said Éric Dessertenne, CEO of BIOCORP.
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com .
1 “Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen ”, Diabetes Technology & Therapeutics, Vol: 22(7), 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210926005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thredd Joins The Visa Agentic Ready Programme, Bringing Agent Network Readiness To Issuers Across Europe, Starting With Zilch15.7.2026 09:00:00 CEST | Press release
Thredd, the AI-first issuer processing platform, today announced it has joined the Visa Agentic Ready programme, enabling issuers across Europe to participate in agent-initiated payments without rebuilding their payments infrastructure. Consumer payments platform Zilch will be among the first issuers on the platform to enable agent-initiated payments for its cardholders. As a processor and enabler, Thredd sits at the trust layer of the payments ecosystem. By joining the programme, Thredd is ready to support Visa and its clients as the market moves into agentic commerce. Agentic commerce introduces a new type of payment initiator: An AI agent acting on a cardholder's behalf. The core payments principles do not change. Cardholder permission, issuer approval, authentication and fraud monitoring all still apply. What changes is how trust is established and enforced at the point an agent transacts. Taking a Zilch customer as an example, a cardholder might ask an AI agent to find a product w
Surgerii Robotics Announces First European Installation of the SHURUI® Single-Port Surgical System at Vall d'Hebron University Hospital15.7.2026 09:00:00 CEST | Press release
Surgerii Robotics today announced the first European installation of its SHURUI Single-Port (SP) Surgical System at Vall d'Hebron University Hospital in Barcelona, Spain, one of Europe's leading academic medical centers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713209503/en/ The first pediatric procedure performed with the SHURUI SP system was a nephroureterectomy on a twelve-year-old boy whose kidney and ureter had become infected and non-functional due to multiple stones. The SHURUI SP system is CE-marked for adult and pediatric use, making it the only CE-marked single-port robotic surgical system currently indicated for pediatric procedures in Europe. The installation marks an important milestone in the international expansion of Surgerii Robotics and the introduction of the technology into a major European reference center. As part of this collaboration, Vall d'Hebron University Hospital has become the first hos
SES, Airbus and Dutch Municipality of Noordwijk to Build Satellite Optical Ground Station for EAGLE-115.7.2026 08:50:00 CEST | Press release
The parties signed a ground lease agreement allowing installation of the optical ground station (OGS) at the NL Space Campus SES, a space solutions company, jointly with Airbus Netherlands B.V. signed a ground lease agreement with the Dutch municipality of Noordwijk for a plot at the NL Space Campus, next to the European Space Agency’s (ESA) technical center ESTeC. The facility will host a dedicated optical ground station (OGS) to communicate with the EAGLE-1 satellite and receive quantum safe keys via laser technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714786947/en/ Breaking the ground of the EAGLE-1 Optical Ground Station, Municipality of Noordwijk, the Netherlands. Pictured left to right: Pim van Strien, Alderman for the Municipality of Noordwijk; Rob Postma, President and Managing Director, Airbus Netherlands; Alan Kuresevic, Managing Director, SES Techcom, SES. The station, to be built by Airbus for SES,
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend15.7.2026 08:00:00 CEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company previously extended that submission deadline to June 30, 2026, and has now further extended that submission deadline to December 31, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before December 31, 2026 in order to facilitate paym
First Trust Global Portfolios Management Limited Announces Distribution for certain sub-funds of First Trust Global Funds ICAV14.7.2026 22:04:00 CEST | Press release
First Trust Global Portfolios Management Limited (“FTGPM”) announces the declaration of the monthly distribution for First Trust Vest S&P 500® Dividend Aristocrats Target Income UCITS ETF (the “Fund”). ISIN Fund Name Frequency Dividend per Share IE000SNMGYT5 First Trust Vest S&P 500® Dividend Aristocrats Target Income UCITS ETF Class B Monthly $0.1472 (USD) The Fund’s investment manager is First Trust Advisors L.P. (“FTA”). FTA has appointed Vest Financial LLC to sub-advise the Fund. The following dates apply to today’s distribution declaration: Expected Ex-Dividend Date: 21 July 2026 Record Date: 22 July 2026 Payable Date: 31 July 2026 About First Trust Advisors L.P. FTA is a privately owned US-based financial services firm and is registered as an investment adviser with the United States Securities and Exchange Commission. FTA acts as adviser to a range of Irish domiciled UCITS funds under the First Trust Global Funds ICAV umbrella. The Funds' distributors are FTGPM and First Trust G
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom